维普中文期刊产品整合服务
144篇 您的检索式:作者名="de AzambujaE"
    题名 作者 年代 出处 被引量
1The17q12-q21amplicon:Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours显示文摘Mano MS Rosa DD De Azambuja E 2007Cancer Treat Rev2007,33,:1
2Trastuzumabfor patients with HER2 positive breast cancer: delivery,duration and combination therapies显示文摘Pinto AC Ades F de Azambuja E ef af 2013Breast2013,,2:1
3Dissecting the heterogeneity of triple-negative breast cancer显示文摘Metzger-Filho O Tutt A de Azambuja E 2012J Clin Oncol2012,30,15:1
4Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation显示文摘Lothaire P de Azambuja E Dequanter D 2006Head Neck2006,28,3:1
5Targeting the PI3K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatmem of breast cancer显示文摘Saini K S Loi S de Azambuja E 2013Cancer Treat Rev2013,39,8:1
6Brain-stem compression syndrome caused by vertebrobasi- lar dolichoectasia: mierovaseular repositioning technique 显示文摘Azambuja Pereira-Filho A de Barros Faria M Bleil C 2008Arq Neuropsiquiatr2008,66,2:1
7Trastuzumab for early breast cancer: current status and future directions 显示文摘Dinh P de Azambuja E Piocart - Gebhart MJ 2007Clin Adv Hematol Oncol2007,5,9:1
8Review: side effects of approved molecular targeted therapies in solid cancers显示文摘Widakowich C de Castro G Jr de Azambuja E 2007Oncologist2007,12,12:1
9Ki-67 as a prog- nostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients 显示文摘de Azambuja E Cardoso F de Casrto G Jr 2007Br J Cancer2007,96,10:1
10Angiogenesis and cancer: a cross-talk between basic science and clinical trials ( the “do ut des” paradigm) 显示文摘de Castro Junior G Puglisi F de Azambuja E 2006Crit Rev Oncol Hematol2006,59,:1
11Dissecting the heterogeneity of triple-negative breast cancer显示文摘Metzger-Filho O Tutt A de Azambuja E 2012J Clin Oncol2012,30,15:1
12Trastuzumab for early breast cancer: current status and future directions显示文摘Dinh P de Azambuja E Piccart-Gebhart MJ 2007Clin Adv tte- matol Oncol2007,5,9:1
13Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTYO) : Survival outcomes of a raudomised, open- label, multiceutre, phase 3 trim and their association with pathological complete response 显示文摘de Azambuja E Holmes AP Piccart-Gebhart M 2014Lancet Oncol2014,15,10:1
14Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients 显示文摘de Azambuja E Cardoso F de Castro G Jr 2007Br J Cancer2007,96,10:1
15Dissec- ting the heterogeneity of triple-negative breast cancer显示文摘Metzger-Filho O Tutt A de Azambuja E 2012J Clin Oncol2012,30,15:1
16Ki- 67 asprognostic marker in early breast cancer: a meta- analysis ofpublished studies involving 12,155 patients显示文摘de Azambuja E Cardoso F de Castro G Jr 2007Br J Cancer2007,96,10:1
17Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer显示文摘Saini KS Loi S de Azambuja E 2013Cancer Treat Rev2013,39,8:1
18Targeting the PI3 K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer显示文摘Saini KS Loi S de Azambuja E 2013Cancer Treat Rev2013,39,8:1
19The 17q12 - q21 amplicon: Her2 and topoisomerase-Ⅱalpha and their importance to the biology of solid tttmours 显示文摘Mano MS Rosa DD De Azambuja E 2007Cancer Treat Rev2007,33,1:1
20Ki- 67 as prognostic marker in early breast cancer: a meta- analysis of published studies involving 12,155 patients 显示文摘de Azambuja E Cardoso F de Castro G Jr 2007BrJ Cancer2007,96,10:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费